Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  CytoTools AG    T5O   DE000A0KFRJ1

Delayed Quote. Delayed  - 03/24 05:36:24 pm
16.34 EUR   +40.86%
02/01 CYTOTOOLS : DermaPro_extended strategy
01/18 CYTOTOOLS : financing.pdf
2016 CYTOTOOLS : announces personnel change
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
11.75(c) 11.775(c) 11.595(c) 11.6(c) 16.34(c) Last
2 596 3 756 5 471 1 010 135 040 Volume
-0.25% +0.21% -1.53% +0.04% +40.86% Change
More quotes
Financials (€)
Sales 2015 1,50 M
EBIT 2015 -1,70 M
Net income 2015 -1,70 M
Finance 2015 3,30 M
Yield 2015 -
Sales 2016 -
EBIT 2016 -1,70 M
Net income 2016 -1,70 M
Finance 2016 2,30 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
EV / Sales2015 19,6x
EV / Sales2016 0
Capitalization 32,7 M
More Financials
Company
CytoTools AG operates as a biotechnology company, which engages in developing therapeutic from research on programmed death cell.The company was founded by Dirk Kaiser and Mark-Andre Freyberg in 2000 and is headquartered in Darmstadt, Germany. 
More about the company
Latest news on CYTOTOOLS AG
03/24 DGAP-NEWS : CytoTools AG: DermaPro(R) erhält Marktzulassung in Indien - ein Meil..
03/24 DGAP-ADHOC : CytoTools AG: DermaPro(R) erhält Marktzulassung in Indien
02/16 DGAP-NEWS : CytoTools AG setzt erneut Patentschutz für DermaPro(R) durch
02/01 CYTOTOOLS : DermaPro_extended strategy
01/31 DGAP-NEWS : Eine erweiterte Strategie soll die Entwicklung der CytoTools AG erhe..
01/18 CYTOTOOLS : financing.pdf
01/12 DGAP-NEWS : Die Gesellschafter der DermaTools Biotech GmbH stellen die Weichen f..
2016 CYTOTOOLS : announces personnel change
2016 DGAP-ADHOC : Die CytoTools AG gibt eine personelle Veränderung im Vorstand bekan..
2016 CYTOTOOLS : DermaTools action for damages
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
2016CytoTools : DermaTools action for damages  
2016#Frankfurt #stocks: CytoTools : #Market Analysts conclude unsteady sales prof.. 
2016BRIEF-Cytotools unit signs contracts for production with German manufacturer ..
1
2016#Frankfurt #stocks: CytoTools : #Merger #Acquisition Analysts say: thin Feb 2.. 
2015#Frankfurt #stocks: CytoTools : #Market Analysts conclude dispiriting sales p.. 
More tweets
Qtime:4
Advertisement
Chart CYTOTOOLS AG
Duration : Period :
CytoTools AG Technical Analysis Chart | T5O | DE000A0KFRJ1 | 4-Traders
Full-screen chart
Technical analysis trends CYTOTOOLS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 11,5 €
Spread / Average Target -30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark-Andre Freyberg CEO & Head-Investor Relations
Manfred May Chairman-Supervisory Board
Dirk Kaiser Chief Research Officer
Markus H. Weissbach Chief Medical Officer
Dieter Tober Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOTOOLS AG90.02%35
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results